Skip to main content

Select Drug Profiles

Convergence: Up Close and Personal

David B. Nash, MD, MBA

David B. Nash, MD, MBA

Original Research

Real-World Treatment Patterns and Healthcare Costs Among Patients with FL with Early Treatment Failure of First-Line Chemoimmunotherapy

Lori A. Leslie, MD, Bruno Emond, MSc, Marie-Hélène Lafeuille, MA, Maude Vermette-Laforme, BSc, Patrick Lefebvre, MA, Qing Huang, PhD, MHS

Lori A. Leslie, MD; Bruno Emond, MSc; Marie-Hélène Lafeuille, MA; Maude Vermette-Laforme, BSc; Patrick Lefebvre, MA; Qing Huang, PhD, MHS

Original Research, Practice Management

Budget Impact of Intravenous Cetirizine Hydrochloride for the Treatment of Acute Urticaria in the Emergency Department Setting

Lisa M. Bloudek, PharmD, MS, LoAn K. Ho, PharmD, Neha Kapur, PharmD, Lonnie D. Brent, PharmD

Lisa M. Bloudek, PharmD, MS; LoAn K. Ho, PharmD; Neha Kapur, PharmD; Lonnie D. Brent, PharmD

Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma

Conference Highlights ASCO

Black Patients with Cancer and COVID-19 More Likely Than White Patients to Have Therapy Disruptions

Conference Highlights ASCO

PD-1 Inhibition with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer

Tafinlar plus Mekinist First Tumor-Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation

Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor

Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey

Infectious Diseases

Peptide-Based CoVac-1 Vaccine Shows Promise Against COVID-19 in Patients with Cancer

Page 14 of 244
Results 131 - 140 of 2438